Celsion (CLSN -6.4%) slides after Brean Capital cut the shares to Sell earlier today. Brean says...

|About: Celsion Corporation (CLSN)|By:, SA News Editor

Celsion (CLSN -6.4%) slides after Brean Capital cut the shares to Sell earlier today. Brean says in a note to clients that the stock has ramped up significantly due to heightened expectations over clinical trials for it's RFAT liver cancer treatment, which is expected this month. The firm calls it "a highly binary event in 1Q13 that, in our view, will define whether or not the company remains viable thereafter." This caution is shared by a Seeing Alpha contributor: Recalculating Celsion's Upcoming Results.